title: [Evaluation of antiangiogenic treatment results in choroidal neovascularization related to pathological myopia].
abstract: BACKGROUND
  Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes.
  
  
  METHODS
  In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment.
  
  
  RESULTS
  The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9 µm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001).
  
  
  CONCLUSIONS
  Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs.
authors.affiliation: Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.. mimed07172@med.up.pt.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Carvalho
authors.affiliation: Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.. mimed07172@med.up.pt.
authors.forename: Paulo
authors.initials: P
authors.lastname: Freitas-Costa
authors.affiliation: Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.. mimed07172@med.up.pt.
authors.forename: João
authors.initials: J
authors.lastname: Pinheiro-Costa
authors.affiliation: Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.. mimed07172@med.up.pt.
authors.forename: Manuel
authors.initials: M
authors.lastname: Falcão
authors.affiliation: Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.. mimed07172@med.up.pt.
authors.forename: Ângela
authors.initials: Â
authors.lastname: Carneiro
authors.affiliation: Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.. mimed07172@med.up.pt.
authors.forename: Fernando
authors.initials: F
authors.lastname: Falcão-Reis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications* / Q000503:physiopathology; D000069579:Ranibizumab; D012189:Retrospective Studies; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab